Cohance Lifesciences Ltd shared the transcript of its earnings call for Q4 FY 2025, highlighting its transformation and ambitions to reach $1 billion in revenue by 2030 with an EBITDA margin of 34%.
AI Assistant
Suven Pharmaceuticals Ltd
2025
Announcement
Find Answers
Ask about any part of the document to get insights, explanations, or key details.